




# EXAGEN AVISE® TESTING IS NOW AVAILABLE THROUGH SONORA QUEST LABORATORIES

Sonora Quest and Exagen Inc., an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, are proud to partner in delivering providers and patients innovative solutions.

*Millions of Americans are suffering from symptoms seen in autoimmune disease such as lupus or rheumatoid arthritis. Seeking an early and accurate diagnosis can be aided with AVISE® CTD, now offered through Sonora Quest.*

## Who should be considered for AVISE CTD?

-  Patients with clinical suspicion of a connective tissue disease
-  Patients who are ANA+ referrals
-  Patients with overlapping symptoms
-  ANA+ fibromyalgia patients suspected of autoimmune disease

Please see the full list of AVISE testing on the reverse page. Innovative testing for diagnosis, prognosis, and monitoring of autoimmune connective tissue diseases to facilitate improved care is now offered through Sonora Quest.



- ✓ View our menu of AVISE tests on the reverse side.
- ✓ For more information please contact your Sonora Quest Laboratories Account Manager, visit [SonoraQuest.com](http://SonoraQuest.com), or call 1.800.766.6721, ext. 5285.

# AVISE® Test Menu

## AVISE Diagnostic, Prognostic and Monitoring Tests

Components will be available to be ordered individually.

Test Name	Test Code	Individual Components	Clinical Use Summary
AVISE® CTD	907088	EC4d, BC4d, Anti-dsDNA (reflex to Crithidia if pos.) ANA (ELISA and HEp-2 IIF), Anti-Sm, Anti-CCP, Jo-1, Scl-70, CENP, SS-B/La, U1RNP, RNP70, R052, Ro60, RNA Pol III, aCL IgG & IgM, β2 GP1 IgG & IgM, RF IgM & IgA)  <i>Order 907096 for CTD w/reflex to SLE Prognostic if Lupus Index is Positive. Order 804117 for CTD &amp; SLE Prognostic.</i>	AVISE CTD is a powerful diagnostic tool to help distinguish overlapping symptoms and aid in the differential diagnosis of RA, SLE, Fibromyalgia, Sjögren's Syndrome, Scleroderma, PM/DM, APS and Autoimmune Thyroid Disease. Included in AVISE CTD is the proprietary AVISE Lupus test.
AVISE® Lupus	907094	EC4d, BC4d, Anti-dsDNA (reflex to Crithidia if pos.) ANA (ELISA and HEp-2 IIF), Anti-Sm, Anti-CCP, Jo-1, Scl-70, CENP, and SS-B/La	AVISE Lupus is a 10-biomarker algorithmic diagnostic test utilizing Cell-Bound Complement Activation Products (CB-CAPs) and SLE associated markers designed to maximize diagnostic accuracy in the detection of SLE with 80% sensitivity and 86% specificity.
AVISE® SLE Prognostic	907089	C1q, Ribosomal P, PS/PT (IgG, IgM), aCL (IgG, IgM, IgA), β2 Gp1 (IgG, IgM, IgA)	AVISE SLE Prognostic is a profile developed to help assess a patient's potential risk for thrombosis, cardiovascular events, lupus nephritis and neuropsychiatric lupus. This profile is beneficial with the AVISE Lupus or AVISE CTD tests to help physicians determine if a given patient has elevated risk for lupus nephritis, manage at risk patients, and help avoid organ involvement at an early stage.
AVISE® SLE Monitor	907090	EC4d, C1q, dsDNA CIA, PC4d, C3, C4  <i>Order 804118 for SLE Monitor and HCQ; 804119 for SLE Monitor and MTX; or 804120 for SLE Monitor and HCQ &amp; MTX</i>	AVISE SLE Monitor is a unique profile of 6 specialized biomarkers to assist physicians anytime they assess the condition of a patient with SLE. This test employs erythrocyte bound C4d (EC4d) and platelet bound C4d (PC4d) along with other markers which have demonstrated significant correlation to clinical improvements in SLE disease activity as well as organ involvement.
AVISE® APS	907091	aCL (IgG, IgM, IgA), β2 GP1 (IgG, IgM, IgA), PS/PT (IgG, IgM)	AVISE APS is a profile of 8 markers to aid in the diagnosis and management of patients with antiphospholipid syndrome (APS). It includes high quality assays included in the diagnostic criteria for APS as well as specialized markers like autoantibodies to the complex phosphatidylserine/prothrombin (PS/PT) which offers improved correlation to LAC compared to other markers.
AVISE® Anti-CarP	907095		AVISE APS is a marker of more severe disease prognosis in RA, independent of Anti-CCP or RF status. It is useful in assessing the risk for joint erosions in an RA patient, especially those with sero-negative RA.
AVISE® MTX	907092		AVISE MTX is an innovative blood test that directly measures the active cellular metabolites of methotrexate, the MTX polyglutamates (MTXPGs) to help assess symptomatic patients who are partial or non-responders after being treated with MTX for more than three months.
AVISE® HCQ	907093		AVISE HCQ is an advanced drug monitoring test that provides accurate measurement of hydroxychloroquine levels in whole blood to help physicians assess their patients' compliance and exposure to HCQ therapy.

### SonoraQuest.com

Sonora Quest Laboratories, any associated logos, and all associated Sonora Quest Laboratories registered or unregistered trademarks are the property of Sonora Quest Laboratories. All third-party marks —® and ™— are the property of their respective owners. © 2020 Sonora Quest Laboratories. All rights reserved. 11/2020